US 10806750
RNAi therapy for hepatitis B virus infection
granted A61KA61K31/713A61K38/16
Quick answer
US patent 10806750 (RNAi therapy for hepatitis B virus infection) held by Arrowhead Pharmaceuticals, Inc. expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K31/713, A61K38/16, A61K47/549, A61K47/554